COMPUGEN LTD (CGEN) Stock News
NASDAQ:CGEN - Nasdaq - IL0010852080 - Common Stock - Currency: USD
CGEN Latest News, Press Relases and Analysis
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of -33.33% and 38.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: AFMD
Compugen Reports First Quarter 2025 Results
Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025 Recruitment ongoing in the first in human...
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -9.09% and 27.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: FBIO
Compugen Announces Leadership Transitions Effective September 2025
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Reports Fourth Quarter and Full Year 2024 Results
Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized...
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of -75% and 91.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BRTX
Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -70.73% and 19.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: RGNX
McKesson (MCK) Tops Q4 Earnings Estimates
McKesson (MCK) delivered earnings and revenue surprises of 3.16% and 3.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MCK
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing...
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Participate in Stifel 2024 Healthcare Conference
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present New Clinical Data at SITC 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present at Single Cell Genomics 2024 Conference
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Reports Second Quarter 2024 Results
FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab,...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
CGEN Stock Earnings: Compugen Beats EPS, Beats Revenue for Q2 2024
CGEN stock results show that Compugen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Compugen to Present at Upcoming Antibody Industrial Symposium
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
CGEN Stock Earnings: Compugen Misses EPS, Misses Revenue for Q1 2024
CGEN stock results show that Compugen missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Compugen Reports First Quarter 2024 Results
Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024 Data from COM701 +...
Compugen Appoints David Silberman as Chief Financial Officer
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Participate in Two Upcoming Investor Conferences
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Compugen (NASDAQ:CGEN) just reported results for the fourth quarter of 2023.Com...
CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023
CGEN stock results show that Compugen missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.